Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial

Mark Woodward, Anushka Patel, Sophia Zoungas, Lisheng Liu, Chang Yu Pan, Neil Poulter, Andrzej Januszewicz, Nikhil Tandon, Prashant Joshi, S Heller, Bruce Neal, John Chalmers

    Research output: Contribution to journalArticlepeer-review

    22 Citations (Scopus)

    Abstract

    OBJECTIVE - Participants in ADVANCE were drawn from many countries. We examined whether the effects of intensive glycemic control on major outcomes in ADVANCE differ between participants from Asia, established market economies (EMEs), and eastern Europe. RESEARCH DESIGN AND METHODS - ADVANCE was a clinical trial of 11,140 patients with type 2 diabetes, lasting a median of 5 years. Demographic and clinical characteristics were compared across regions using generalized linear and mixed models. Effects on outcomes of the gliclazide modified release-based intensive glucose control regimen, targeting an HbA lc of ≤6.5%, were compared across regions using Cox proportional hazards models. RESULTS - When differences in baseline variables were allowed for, the risks of primary outcomes (major macrovascular or microvascular disease) were highest in Asia (joint hazard ratio 1.33 [95% CI 1.17-1.50]), whereas macrovascular disease was more common (1.19 [1.00-1.42]) and microvascular disease less common (0.77 [0.62-0.94]) in eastern Europe than in EMEs. Risks of death and cardiovascular death were highest in eastern Europe, and the mean difference in glycosylated hemoglobin between the intensive and standard groups was lowest in EMEs. Despite these and other differences, the effects of intensive glycemic control were not significantly different (P≥0.23) between regions for any outcome, including mortality, vascular end points, and severe hypoglycemic episodes. CONCLUSIONS - Irrespective of absolute risk, the effects of intensive glycemic control with the gliclazide MR-based regimen used in ADVANCE were similar across Asia, EMEs, and eastern Europe. This regimen can safely be recommended for patients with type 2 diabetes in all of these regions.

    Original languageEnglish
    Pages (from-to)2491-2495
    Number of pages5
    JournalDiabetes Care
    Volume34
    Issue number12
    DOIs
    Publication statusPublished - Dec 2011

    Fingerprint Dive into the research topics of 'Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial'. Together they form a unique fingerprint.

    Cite this